deucravacitinib (Sotyktu)

following a full submission:

deucravacitinib (Sotyktu®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.

In two phase III studies, deucravacitinib was superior to a phosphodiesterase type-4 inhibitor and placebo in improving the signs and symptoms of psoriasis in adults with moderate to severe plaque psoriasis, who were candidates for systemic therapy.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.